PCI Biotech Holding ASA

PCI Biotech Holding ASA is rated 3 out of 5 in the category biotechnology. Read and write reviews about PCI Biotech Holding ASA. PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaCHEM (enhancement of chemotherapeutics for localised treatment of cancer), fimaVACC (T-cell induction technology for therapeutic vaccination), and fimaNAC (nucleic acid therapeutics delivery). Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead fimaCHEM programme consists of a clinical Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVACC applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaVACC is currently in phase I in healthy volunteers. fimaNAC utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field. The collaborative fimaNAC programme is in preclinical stage with established research collaborations with key players in the field PCI Biotech was established 2000 and is since June 2008 listed on the Oslo Stock Exchange (Axess). The company is headquartered in Oslo, Norway.